Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...

Background: Optimizing the diagnosis and treatment of hematological diseases is a challenging yet crucial research area. Effective treatment plans typically require the comprehensive integration of ...

Keros’ lead product candidate, elritercept, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients ...

Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...

from the blood, and that correlates with progression-free survival and overall survival benefit. That is the standard for every disease except for myelofibrosis because I think it's just been ...

Gene-edited stem cells can be used in regenerative ... people from three genetic-disease backgrounds: β-thalassaemia, an inherited disorder that affects red blood cells; Wiskott–Aldrich ...

Those stem cells are then transferred to the person suffering from leukemia, lymphoma or other blood disorders and cancers. Today, most stem cell transplants are done through peripheral blood stem ...

These cells can spread throughout the body and block healthy blood cells from growing. Myelofibrosis is a type of blood cancer that's very similar to the end stages of polycythemia vera.